Login
$ACRV
$1.45 -$0.01 (0.68%) Pre-market

Company Executives

Officer Age In this role 2025 pay Source
Peter Blume-Jensen Also a director
Chief Executive Officer, President, and Chairman of the Board
64 Not stated $2,718,538
Adam Levy
Chief Financial Officer
61 Since 2025
1 year
Not reported
Eric Devroe
Chief Operating Officer
48 Since 2022
4 years
$1,358,003
Mary-Alice Miller
Chief Legal Officer
52 Since 2023
3 years
Not reported
Mansoor Raza Mirza
Chief Medical Officer
65 Since 2025
1 year
Not reported
Erick Gamelin
Chief Development Officer
69 Since 2024
2 years
Not reported
Michaela Levin
Chief Business Officer
Title from the Form 4 dated Aug 31, 2026
Not stated Not stated Not reported
Katharine Peterson
Chief Accounting Officer
Title from the Form 4 dated Aug 18, 2026
Not stated Not stated Not reported
Kristina Masson Also a director
Executive Vice President, Business Operations, and Director
46 Not stated $1,424,926

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
4.8 years
from year joined
CEO also chairs the board
Yes
Peter Blume-Jensen
Director Age On board Independent Committees Other public boards 2025 pay Source
Peter Blume-Jensen
64 2018
8 years
Not independent None stated None stated Paid as CEO
Kristina Masson
46 2018
8 years
Not independent None stated None stated Not stated
Michael Tomsicek
60 2022
4 years
Independent
Audit Committee · Chair
Milestone Pharmaceuticals USA, Inc. $72,870
Charles Baum
68 2023
3 years
Independent
Compensation Committee · Chair
PMV Pharmaceuticals, Inc. Not stated
Sharon Shacham
55 2020
6 years
Independent
Compensation Committee
Nasus Pharma, Ltd. Not stated
Ivana Magovčević-Liebisch
58 2024
2 years
Independent
Audit Committee
Draig Therapeutics, Ltd. Not stated
Derek DiRocco
45 2021
5 years
Independent
Audit Committee
Mineralys Therapeutics, Inc. Not stated
Santhosh Palani
43 2024
2 years
Independent
Nominating and Governance Committee · Chair
Pyxis Oncology Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 30, 2026
RA Capital Healthcare Fund, L.P.
a beneficial owner of greater than 5% of our capital stock
$30,005,000
April 8, 2024

Purchased 3,530,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Perceptive Life Sciences Master Fund, Ltd.
a beneficial owner of greater than 5% of our capital stock
$20,000,500
April 8, 2024

Purchased 2,353,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Sands Capital Life Sciences Pulse Fund II, L.P.
a beneficial owner of greater than 5% of our capital stock
$3,995,000
April 8, 2024

Purchased 470,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Citadel CEMF Investments Ltd.
an entity affiliated with Citadel Advisors LLC, a beneficial owner of greater than 5% of our capital stock
$3,995,000
April 8, 2024

Purchased 470,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support